Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Urinary Bladder Neoplasms 2Uterine Cervical Dysplasia 1Tongue Neoplasms 1Stomach Neoplasms 1Squamous Intraepithelial Lesions 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Paranasal Sinus Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma, Basal Cell 1

Interventions

HhAntag691 21Biopsy 11Imiquimod 10Aminolevulinic Acid 9sonidegib 8Photochemotherapy 8Nivolumab 81-phenyl-3,3-dimethyltriazene 7methyl 5-aminolevulinate 6cemiplimab 6Surgical Procedures, Operative 5Specimen Handling 5Radiotherapy 5Itraconazole 5pembrolizumab 4daromun 4Mohs Surgery 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Curettage 4Tomography, Optical Coherence 3Standard of Care 3Niacinamide 3Microscopy, Confocal 3IPI-926 3CTLA-4 Antigen 33-ingenyl angelate 3tazarotene 2talimogene laherparepvec 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Basal Cell × Chemoprevention × Clear all
NCT00025051 2013-03-22

Celecoxib in Preventing Skin Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡